Oncology Day One's big bet on tovorafenib just keeps paying off Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.
Market Access JPM 2026: What it revealed about biotech’s new reality JPM 2026 signalled genuine recovery – but not the kind the industry has historically celebrated.
Oncology Daiichi Sankyo gears up for five ADC launches in 2026 On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.
Oncology After 'Year of Harvest', Bayer looks to diversify modalities Bayer Oncology's strategy has led to strong showings in small molecules and radiotherapies. Now they're on the hunt for ADCs, bispecifics, and more.
R&D On JPM2026 and healthcare investment today, with Jonah Comst... Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.
Patients New hope for ovarian cancer, with Alexander Schneider Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.